Global Cardiovascular Partnering 2023: Trends, Players and Financials for Every Deal Since 2016
Global Cardiovascular Partnering 2016 to 2023 provides the full collection of cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
- Trends in cardiovascular partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Cardiovascular partnering agreement structure
- Cardiovascular partnering contract documents
- Top cardiovascular deals by value
- Most active cardiovascular dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering cardiovascular deals.
The report presents financial deal terms values for cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of cardiovascular dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in cardiovascular dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading cardiovascular deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active cardiovascular dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the
Chapter 5 provides comprehensive access to cardiovascular deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the
Chapter 6 provides a comprehensive directory of all cardiovascular partnering deals by specific cardiovascular target announced since 2016. The chapter is organized by specific cardiovascular therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all cardiovascular partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in cardiovascular partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cardiovascular technologies and products.
Report scope
Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to cardiovascular trends and structure of deals entered into by leading companies worldwide.
Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials includes:
- Trends in cardiovascular dealmaking in the biopharma industry since 2016
- Access to headline, upfront, milestone and royalty data
- Access to over 850 cardiovascular deal records
- The leading cardiovascular deals by value since 2016
The report includes deals for the following indications: Abdominal aortic aneurysm, Angina, Arrhythmia, Atrial fibrillation, Long QT syndrome, Supraventricular Tachycardia, Ventricular fibrillation, Ventricular tachycardia, Atherosclerosis, Breathlessness, Cardiogenic shock, Cardiomyopathy (heart muscle disease), Chest pain, Congenital heart disease, Congestive heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular heart disease, Aortic stenosis, Restenosis, Varicose veins, plus other cardiovascular indications.
In Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 850 cardiovascular deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Selection of Companies Mentioned
1A Pharma - 3PrimeDx
- 4D Molecular Therapeutics
- 4D Pharma
- 4SC Discovery
- 36 Strategies General Trading
- 480 Biomedical
- A&D Medical
A&E Medical - A*
STAR Agency for Science - Technology and Research
- AADi
- Abbott Laboratories
Abbott Vascular Devices - Abiomed
Ab Medica - Abyrx
- Acasti Pharma
- Accenture
- Access Scientific
- Access Vascular
- ACEA Biosciences
Acino Pharma - Actelion
- Actuated Cardio Engineering
- Actuated Medical
- Acutus Medical
- ADAS 3D Medical
- AddUp
- Admedus
Admera Health Advanced BioScience Laboratories - Advanced Cardiac Therapeutics
- Advanced Catheter Therapies
- Advanced Cooling Therapy
Adventus Ventures - Aegerion Pharmaceutical
- Aerolase
Agena Bioscience - Agilent Technologies
Akcea Therapeutics - Akers Biosciences
- Akrimax Pharmaceutical
Akums Drugs and Pharmaceuticals Alibaba Health AliveCor Allegiance Health Foundation - Allergan
- Alliance Medical
- Alnylam Pharmaceuticals
- Altrix Medical
- Amarin
- Amarna Therapeutics
American College of Emergency Physicians American College of Physicians Foundation American College of Surgeons American Heart/Stroke Association American Heart Association - AmeriCares
- Amgen
- Amneal Pharmaceuticals
- AmorChem
Amos Gazit - AnaBios
- Analog Devices
AnaMar Angel Medical Systems - AnGes MG
- Angiodynamics
- Angion Biomedica
- Angionetics
AngioSoma - ANI Pharmaceuticals
- Antares Pharma
- Antaros Medical
- Anthem
- Anthos Therapeutics
AOP Orphan Pharmaceuticals - APAC Scientific
Apicore - Aplagon
Apollo Hospitals Group - Apotex
- Apple
- Applied Medical
- Aptahem
Aralez Pharmaceuticals - Ardelyx
- Arena Pharmaceuticals
- argenx
Argon Medical Devices Armetheon - Aronora
- Arrowhead Pharmaceuticals
- Arteriae
Arterial Health International Arterial Remodeling Technologies - Asahi Intecc
Ashland-Boyd County Health Department ASKA Pharmaceuticals - Aspen Global
Aspen Holding - Aspire Health Science
- Astellas Pharma
- AstraZeneca
AstraZeneca HealthCare Foundation - Atelerix
- Athersys
- Atnahs Pharma
AutoGenomics - Autotelic
Aviir Diagnostics - Awamedica
Axiogenesis - Axol Bioscience
- Aziyo Biologics
Baker IDI Heart and Diabetes Institute Bardy Diagnostics - Baxter International
- Bayer
Bayer Healthcare Bay Labs - B Braun
- Beijing Leadman Biochemistry
- Beijing SL Pharma
- Bellerophon Therapeutics
- Bened Biomedical
- Berg
- Bertin Pharma
Bicycle Therapeutics - Bina Technologies
- BioCardia
Bioengineering Laboratories - Biofourmis
- BioHeart
- BioLamina
- BIOLIFE4D
- BioLife Solutions
Biomerics - BioSig Technologies
- Biostar
Biostar Pharmaceuticals - Biotectix
- BioTelemetry
- Biotricity
- Biotronik
BioVectra - Bioventix
Biovic Sdn bhdBird Foundation - BlueRock Therapeutics
- BodyTrace
Boehringer Ingelheim - Boryung Pharmaceutical
Boston Medical Center Boston Pharmaceuticals - Boston Scientific
Breckenridge Pharmaceuticals Brigham and Women's Hospital Brigham Young University - Bristol-Myers Squibb
Broad Institute - Brooks Automation
- Burgerhospital
Cadila Pharmaceuticals - Caladrius Biosciences
California Institute for Regenerative Medicine California Institute of Technology Canadian Institutes of Health Research - Capellabio
- Capricor Therapeutics
- Caprion Proteomics
- Cardiac Insight
- Cardiac Life
- Cardinal Health
CardiNor Cardio3 Biosciences Asia Holdings - CardioDx
CardioFocus - CardioLogic
- Cardiome Pharma
Cardiorentis - Cardiovascular Cell Therapy Research Network
Cardiovascular Research Foundation - Cardiovascular Systems
- Cardiowise
- Cardium Therapeutics
Cardurion Pharmaceuticals - CareDx
- CareLearning
Carestream Health - CareTaker Medical
- Carmat
Carmel Pharma Carrum Health - Casebia Therapeutics
Case Western Reserve University - CASI Pharmaceuticals
CAS Medical Systems - Catherine's Health Center
- Catheter Precision
CDC Foundation Cedars-Sinai Health System Cedars-Sinai Medical Center - Celgene
Celladon - Cell and Gene Therapy Catapult
CELLINK - CellProThera
Cell Therapy Celltrion - Cellular Logistics
- CeloNova BioSciences
- Celyad
Center for Biomarker Research in Medicine Center for Connected Health Centers for Medicare and Medicaid Services Centron Diagnostics Cevec Pharmaceuticals - Chameleon BioSurfaces
- Charles River Laboratories
Chek Diagnostics Chiesi Farmaceutici Children's Heart Foundation Children's Hospital Boston Children's Hospital of Philadelphia Children's Medical Research Institute Children's Hospital Oakland Research Institute (CHORI)China Grand Pharmaceutical - China Medical System
Chinese Future Industry Investment Fund Chinese Society of Cardiology - Chong Kun Dang
Christiana Care Health System Cilag AG - C Illies
- CinCor Pharma
- Cipher Pharmaceuticals
Cipla Medpro - Citius Pharmaceuticals
- Clarity Pharmaceuticals
- ClearFlow
Cleveland Clinic Cleveland HeartLab - Clinlogix
Coeptis Pharmaceuticals - Cofactor Genomics
- Colibri Heart Valve
College of Life Science of Northwest University Columbia University Medical Center Conavi Medical Concordia Healthcare - Contatti Medical
- Cook Medical
- Coqui RadioPharmaceuticals
- Cordis
- CorDynamics
- CoreRx Pharma
Corindus Vascular Robotics CorMatrix Cardiovascular - Coroneo
- CorpMedical
- Correvio
- CorVascular
- Corvia Medical
- Corvida Medical
Corvidia Therapeutics - Covalon Technologies
- Covance
- Covidien
- Covis Pharmaceutical
Cranford Pharmaceuticals - CRISPR Therapeutics
Critical Diagnostics - Crown Bioscience
- Cryolife
- CSL
- Cure Duchenne
- CVie
- CyberHeart
- Cyclenium Pharma
- Cynata Therapeutics
- Cytori Therapeutics
- CytoSorbents
- Daewoong Pharmaceutical
- Daiichi Sankyo
DalCor Pharmaceuticals Dalhousie University - Dassault Systems
- DaVinci Biomedical Research Products
DecImmune Therapeutics - deCODE Genetics
- Delta
- Deltex Medical
- Denovo Biopharma
Department of Defense Department of Health and Human Services - Dewpoint Therapeutics
Diablo Clinical Research - diaDexus
- DiA Imaging Analysis
- Diaxonhit
- Dicerna Pharmaceuticals
- DiNAQOR
- Dizal Pharmaceutical
- Dogma Therapeutics
- Domainex
- Dorizoe Lifesciences
- Dr. Reddy's Laboratories
Drukier Institute for Children's Health - DSM
- Duke-NUS Graduate Medical School Singapore
Duke Clinical Research Institute (DCRI)Duke University - Duke
University Medical Center - Eagle Pharmaceuticals
- EB Neuro
- eCardio Diagnostics
Eddingpharm - Edwards Lifesciences
- Eiger BioPharmaceuticals
- Eko
ELC Group - Electrical Geodesics
- Elexopharm
- Eli Lilly
Elkhorn Logan Valley Public Health Department - Embolitech
- EmboMedics
Emory University - Enamine
- Endo International
- Endologix
- Endospan
Endotronix Enterprise Partners Venture Capital - ENYO Pharma
- Epsilon
- Erasmus
University Medical Center - ERS Genomics
- ERT
Esaote - Esperion Therapeutics
Espero Pharmaceuticals - Eurolab Especialidades Medicinales de Eurofar
European Commission European Innovation Council - Event
Cardio Group - Everest Medicines
- Excelera Network
- Exelixis
- Expression Analysis
ExScientia - FABPulous
Feinstein Institute for Medical Research - FEops
- FibriCheck
- Fine Foods & Pharmaceuticals N.T.M.
First Check Diagnostics - FitBit
Food and Drug Administration (FDA)Foundation for Community Partnerships Frankfurt University Hospital - FSD Pharma
- Fujifilm
- Fujifilm medical systems
- Fundacion Progreso y Salud
Fu Wai Hospital G3 Pharmaceuticals Galenicum Health - Gardia Medical
For more information about this report visit https://www.researchandmarkets.com/r/f6hila
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For
For GMT Office Hours Call +353-1-416-8900
Fax (outside
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-cardiovascular-partnering-2023-trends-players-and-financials-for-every-deal-since-2016-301789832.html
SOURCE
